DEA Greenlights Opium Imports for Siegfried USA—Legal Highs Ahead?
Published Date: 1/22/2026
Notice
Summary
Siegfried USA, LLC wants to become an official importer of certain controlled substances, like phenylacetone and raw opium. This affects companies handling these drugs and anyone interested can comment or request a hearing by February 23, 2026. No direct costs are mentioned, but this move could impact drug supply chains and regulations.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Comment and Hearing Deadline
Registered bulk manufacturers and applicants can submit electronic comments or objections about Siegfried USA, LLC's importer application, or file a written request for a hearing, on or before February 23, 2026. Comments must be submitted through https://www.regulations.gov and hearing requests must be sent to the DEA addresses listed in the notice.
Importer Application for Schedule II APIs
Siegfried USA, LLC applied on November 27, 2025 to be registered to import the Schedule II substances phenylacetone (code 8501), opium, raw (code 9600), and poppy straw concentrate (code 9670). The company states it plans to import these substances only to manufacture bulk active pharmaceutical ingredients for distribution to its customers, and the registration will not authorize import of finished dosage forms for commercial sale.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-13825 — Designation of Phenethyl Halides as List I Chemicals
The DEA wants to add phenethyl halides to a special list of chemicals that are closely watched because they can be used to make illegal fentanyl. This means anyone handling these chemicals will have to follow new rules starting soon, no matter how much they have. If you work with these chemicals, get ready to comply and share your thoughts by August 10, 2026!
2026-13821 — Schedules of Controlled Substances: Placement of Tianeptine in Schedule I
The DEA wants to put tianeptine, a drug with potential risks, into Schedule I, meaning it’ll be treated like the most tightly controlled substances. This change affects anyone who makes, sells, studies, or uses tianeptine, bringing strict rules and penalties. You’ve got until August 7, 2026, to share your thoughts before the new rules could kick in.
2026-13705 — Importer of Controlled Substances Application: Benuvia Operations, LLC.
Benuvia Operations, LLC wants to become an official importer of certain controlled substances like marijuana extract and psilocybin. People and companies involved with these drugs can share their thoughts or ask for a hearing by August 6, 2026. This move could shake up who gets to bring these substances into the U.S., so keep an eye on the deadline if you’re interested!
2026-13581 — Schedules of Controlled Substances: Temporary Placement of Mitragynine Pseudoindoxyl, MGM-15, and MGM-16 in Schedule I
Starting July 6, 2026, the DEA plans to temporarily put three substances related to 7-hydroxymitragynine—Mitragynine Pseudoindoxyl, MGM-15, and MGM-16—into Schedule I, the strictest drug category. This means anyone making, selling, or using these chemicals will face tough legal rules and penalties. The move aims to control these substances quickly while the DEA studies them further, affecting businesses and researchers handling these compounds.
Previous / Next Documents
Previous: 2026-01193 — L-Lysine From the People's Republic of China: Preliminary Affirmative Countervailing Duty Determination and Alignment of Final Determination With Final Antidumping Duty Determination
The U.S. government found that Chinese companies making L-lysine, a common animal feed ingredient, are getting unfair financial help from their government. Because of this, the U.S. plans to add extra taxes (countervailing duties) on these imports to keep things fair for American businesses. This decision starts January 22, 2026, and could affect prices and trade between the U.S. and China.
Next: 2026-01195 — Notice of Intent To Extend and Revise a Previously Approved Information Collection
The USDA’s National Institute of Food and Agriculture plans to extend and update the Expanded Food and Nutrition Education Program’s data collection for three more years. This affects educators and volunteers teaching nutrition to families with limited money across all 50 states and territories. They’re asking for public comments by March 23, 2026, to help improve how they track and boost the program’s impact.